20 Feb 2013

Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA). (Antimicrob Agents Chemother., abstract, edited)

[Source: Antimicrobial Agents and Chemotherapy, full text: (LINK). Abstract, edited.]

Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA).

B.J. Werth 1, C. Vidaillac 1, K.P. Murray 1, K.L. Newton 1, G. Sakoulas 3,4, P. Nonejuie 5, J. Pogliano 5 and M.J. Rybak 1,2

Author Affiliations: 1Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences 2School of Medicine 3Wayne State University, Detroit, MI 48201 4Department of Pediatric Pharmacology and Drug Discovery, University of California San Diego School of Medicine, La Jolla, CA USA 5University of California San Diego Division of Biology, La Jolla, CA USA

 

ABSTRACT

We demonstrated a significant inverse correlation between vancomycin and beta-lactam susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA) isolates. Using time kill assays, vancomycin plus oxacillin or ceftaroline was synergistic against 3/5 VISA and 1/5 hVISA or 5/5 VISA and 4/5 hVISA, respectively. Beta-lactam exposure reduced overall vancomycin-bodipy binding but may have improved vancomycin-cell wall interactions to improve vancomycin activity. Further research is warranted to elucidate the mechanism behind vancomycin and beta-lactam synergy.

 

FOOTNOTES

Corresponding Author: Michael J. Rybak, Anti-Infective Research Laboratory, Pharmacy Practice — 4148, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Ave., Detroit, MI 48201, Tel: (313) 577-4376, Fax: (313) 577-8915, Email: m.rybak@wayne.edu

Copyright © 2013, American Society for Microbiology. All Rights Reserved.

-

-------